HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
TerminatedNCT03206463

Cognitive and Psychophysiological Effects of Delta-9-Tetrahydrocannabinol in Bipolarity

Medication studyAges 18–55United States
The study in practice

Understand this study

Who could participate?

Listed age limits: 18 years to 55 years.

Listed locations
West HavenSee all locations and recruitment
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: August 1, 2017
Recruitment status
Terminated
Enrollment listed in the registry
2
Sponsor
Yale University
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
United States
Age range
From 18 Years to 55 Years
Official registry ID
NCT03206463
Official title
Show the full official title

Cognitive and Psychophysiological Effects of Delta-9-Tetrahydrocannabinol in Bipolar Disorder

Recruitment & locations

Terminated

West Haven

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Yale University, a university.

Does this study involve medication?

Yes. The study involves medication, including 4 mg Delta-9-THC, Placebo and 2 mg Delta-9-THC.

Who can participate?

Listed age limits: 18 years to 55 years.

Is this study still recruiting?

The registry lists this study as terminated.

Want to explore more studies?

Explore studies